Imidazo(2,1-B)Thiazole, 2,3,5,6-Tetrahydro-6-Phenyl-, (S)-, Phosphate (1:1)

Designated under the IUPAC name imidazo[2,1-b]thiazole, 2,3,5,6-tetrahydro-6-phenyl-, (S)-, phosphate (1:1) and commonly recognized as Levamisole Phosphate, this chiral active pharmaceutical ingredient (API) is supplied as the 1:1 stoichiometric salt of the (S)-enantiomer of tetramisole with phosphoric acid. The molecular formula C₁₁H₁₂N₂S · H₃PO₄ corresponds to a relative molecular mass of 302.29 g·mol⁻¹ (CAS 32096-60-9). The substance crystallizes as a white to off-white, odorless powder in its thermodynamically stable monohydrate form and functions primarily as a broad-spectrum anthelmintic and immunomodulator in veterinary medicine. Unlike the racemic tetramisole phosphate, the (S)-isomer presents twice the anthelmintic potency while reducing the incidence of cholinergic adverse effects, a differentiation rooted in the stereospecific affinity for nicotinic acetylcholine receptors on nematode muscle membranes. Manufacturing of the phosphate salt involves a chiral resolution step—typically through diastereomeric salt formation with dibenzoyl-d-tartaric acid—prior to salt precipitation with orthophosphoric acid in a solvent system that enforces an enantiomeric excess exceeding 98.5%. The process is validated to deliver a specific optical rotation [α]_D²⁰ between −126° and −130° (c = 1 in water, USP <781>), a parameter monitored by polarimetry equipped with a high-pressure sodium lamp at 589 nm. Residual solvent levels, controlled under ICH Q3C guideline option 2, are routinely kept below 500 ppm for ethanol and 60 ppm for dichloromethane in the final milled product.

Pharmacopoeial Specifications and Purity Profiles

Conformance to the United States Pharmacopeia (USP) monograph “Levamisole Phosphate” and the European Pharmacopoeia (Ph. Eur.) monograph 01/2010:1813 is verified through a battery of compendial tests. Assay by non-aqueous titration with perchloric acid, utilizing crystal violet indicator, yields a levamisole phosphate content not less than 98.5% and not more than 101.0% on the anhydrous basis. Chromatographic purity by reversed-phase HPLC (C18 column, 5 µm, 250 × 4.6 mm; mobile phase: phosphate buffer pH 3.0/acetonitrile 85:15 v/v; detection at 215 nm) ensures individual unspecified impurities remain below 0.10% and total impurities below 0.5%. The tetramisole-related compound B (cis-isomer) is particularly controlled at a maximum of 0.2%. Enantiomeric purity is determined by chiral HPLC using an amylose tris(3,5-dimethylphenylcarbamate) column with a mobile phase of hexane/ethanol/diethylamine 90:10:0.1; the target (S)-enantiomer peak area must account for ≥ 99.0% of the total peak area of both enantiomers. Sulfated ash remains at or below 0.1%, heavy metals (Method II, USP <231>) at fewer than 20 ppm, and loss on drying (105°C for 4 hours) at 5.0–7.0%, corresponding to the monohydrate water content. Residual solvents abide by USP <467> Option 1.

On a production scale, the particle-size distribution is adjusted by jet milling to a d₉₀ below 30 µm, a specification that supports content uniformity in direct-compression tablet formulations. Bulk density, typically 0.45–0.65 g/mL, is determined according to USP <616> Method I and influences hopper flow during encapsulation. The phosphate salt withstands dry heat sterilization at 160°C for 2 hours with less than 0.3% degradation when protected from moisture, making it suitable for sterile powder filling lines.

Why Prefer the Phosphate Salt Over Hydrochloride for Medicated Feed Premixes?

Plant-scale premix manufacturing exposes both salt forms to elevated humidity and temperature cycles inside paddle ribbon blenders and twin-screw extruders used for incorporating anthelmintics into mineral–molasses carriers. Levamisole hydrochloride (CAS 16595-80-5) absorbs moisture above 55% relative humidity at 25°C, as shown by dynamic vapor sorption isotherms, leading to caking, bridging in the hopper, and non-uniform distribution in finished feed blends. In contrast, the phosphate monohydrate maintains a critical relative humidity of 85% at the same temperature, a property that permits storage and processing without the need for desiccated air-handling systems. This difference directly impacts content uniformity: batches produced with the phosphate salt consistently achieve RSD values below 3.5% in USP <905> uniformity-of-dosage-units testing on 10 finished feed samples, whereas hydrochloride-based premixes stored under tropical warehouse conditions for 3 months exhibit segregation-driven RSDs exceeding 8%. Moreover, the phosphate salt is less corrosive to mild-steel mixing equipment; chloride ions from the hydrochloride have been documented to cause pitting corrosion rates of 0.15 mm/year on 316L stainless steel in the presence of moisture, although phosphate-mediated corrosion is not negligible and mandates routine passivation procedures.

Pelletized feed incorporating levamisole phosphate is routinely manufactured on a Buhler DFP type pellet mill equipped with a 4.0 mm die. Processing at conditioning temperatures between 70°C and 80°C with a residence time of 30–45 seconds results in API recovery exceeding 96% of label claim, whereas the hydrochloride analog undergoes approximately 5–8% thermolytic degradation under identical parameters, forming a violet Maillard-type product observable by HPLC. This thermal tolerance reduces costly overage requirements and simplifies downstream assay adjustment in commercial feed mills.

When Formulating Oral Drench Solutions, Solubility Benchmarks Govern Salt Selection

While the hydrochloride offers a higher aqueous solubility—roughly 200 mg/mL at 25°C compared to approximately 100 mg/mL for the phosphate—its use in ready-to-use drenches delivered via drench guns requires tight pH control. Levamisole hydrochloride solutions exhibit a free chloride ion concentration that, below pH 3.0, accelerates corrosion of stainless-steel dosing nozzles, leading to inconsistent shot volumes after as few as 5,000 actuations on standard Simcro variant systems. The phosphate salt, dissolved at a target levamisole base concentration of 30 mg/mL, produces a buffered solution with an intrinsic pH of 4.2–4.5, eliminating the need for additional citrate or phosphate buffer systems. Preparing a 15% w/v levamisole base equivalent drench with the phosphate requires mechanical stirring under high-shear at 800–1,200 rpm for 20 minutes at 40°C; undissolved fines, if present beyond 0.2%, must be removed through a 10 µm in-line filter to prevent clogging in the drench nozzle. The resulting solution, protected from light and packed in amber polyethylene terephthalate bottles, retains an assay value within 98–102% of label for 24 months at 25°C/60% RH. Published kinetic data for phosphate-specific hydrolytic degradation indicate a pseudo-first-order rate constant k ≤ 1.2 × 10⁻⁴ day⁻¹ under those conditions, with the main degradant identified as 3-(2-mercaptoethyl)-5-phenylimidazolidin-2-one via LC-MS. The hydrochloride counterpart demonstrates a hydrolysis rate roughly 1.8-fold faster in unbuffered systems, emphasizing the phosphate’s self-buffering advantage in field-use settings where water quality varies.

Forced Degradation Studies as Predictors of Shelf-Life in Tropical Climates

Stability protocols aligned with ICH Q1A(R2) employ chamber configurations exposing bulk phosphate powder to 40°C/75% RH (Zone IVb simulation) and 50°C/75% RH. Under the latter stress condition for 30 days, enantiomerization to the (R)-isomer remains below 0.15% by chiral HPLC, and total organic impurities increase by less than 0.3%, confirming that racemization via a thiazolidine ring-opening mechanism is sterically impeded. Alkaline pH poses the primary risk: dissolution in carbonate buffer at pH 10.5 and 60°C for 4 hours generates 2.8% of the R-antipode, whereas pH 7.4 phosphate buffer yields no detectable racemization. This boundary forces formulators to avoid alkaline binders—calcium carbonate, magnesium oxide, or strongly basic ion-exchange resins—when producing granulated premixes. Photostability according to ICH Q1B Option 2 (near-UV and cool white fluorescent light, 1.2 million lux·h plus 200 W·h/m²) reveals a 0.7% loss in assay and a visible discoloration to pale yellow after exposure well above 20 kLux; therefore, opaque packaging or light-protective coatings are mandatory for oral boluses intended for strip packaging in transparent blisters.

Enantiomeric Excess and the Therapeutic Window: Beyond 98% ee the Toxicological Profile Shifts

Pharmacological differentiation between the (S)- and (R)-enantiomers arises from their distinct binding affinities at the levamisole-sensitive nicotinic acetylcholine receptor (L-AChR) subtype of Haemonchus contortus. The (S)-form elicits depolarization at an EC₅₀ of 2.3 µM, while the (R)-isomer requires 18 µM, as measured by two-microelectrode voltage clamp on heterologously expressed receptors. At the mammalian ganglionic α3β4 receptor, the (R)-enantiomer displays an EC₅₀ of 8 µM, contributing to salivation and lacrimation when total (R)-content exceeds 2.0% in administered doses. For a standard sheep drench delivering 7.5 mg/kg levamisole base, a drop in enantiomeric excess from 99.0% to 96.5% could theoretically raise the circulating (R)-concentration above the threshold for muscarinic side effects, though published toxicokinetic data for this precise boundary in ruminants remains limited. Consequently, the specification floor of 99.0% (S)-enantiomer by chiral area normalization is not only a purity marker but a safety index; every production batch is accompanied by a chiral chromatogram and a certificate of analysis detailing the optical rotation and impurity profile. The phosphate salt exhibits no measurable enrichment of the (R)-antipode during tableting on a Killian tablet press at compression forces up to 25 kN, confirming that mechanical stress does not induce detectable stereochemical inversion. Nonetheless, caution is warranted when the phosphate is co-milled with polyvinylpyrrolidone-based binders that generate localized basic microenvironments; in such cases, pre-blending with microcrystalline cellulose of pH 5.5–6.5 before binder addition mitigates base-catalyzed racemization during the wet granulation phase.